Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.06, versus $0.00 reported last year. Revenue for the quarter came in at $11.5 million versus the consensus estimate of $0 .

GUIDANCE:

Interpace Biosciences sees FY2025 revenue of $38 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.